What kind of redundancy will there be in G.I. after the divestiture of HyClone? The redundancy IS the HyClone business, which is being divested. The reduction in headcount due to redundancy will be the personnel at HyClone, who will go to a new company. There could be some small RIF in GI from HR, IT or Finance, but it's pretty clear that the Gibco business in general will emerge intact. What else is at GI (other than the cell culture/Gibco bra nd) that is susceptible to downsizing?
↧